Related Experiment Video

Updated: May 21, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways

Vaishalee P Kenkre1, Brad S Kahl

  • 1University of Wisconsin, Madison, WI 53705, USA. vpkenkre@medicine.wisc.edu

Current Hematologic Malignancy Reports
|June 13, 2012
PubMed

Insights

Targeting B cell receptor signaling pathways with tyrosine kinase inhibitors shows promise for treating B cell lymphomas. These inhibitors, targeting kinases like Syk, BTK, and PI3K, demonstrate significant activity in relapsed and refractory cases.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Tonic signaling via the B cell receptor (BCR) promotes growth and survival in B cell lymphomas.
  • Disrupting BCR signaling can induce lethality in malignant B cells.

Purpose of the Study:

  • To discuss the rationale for targeting BCR signaling pathways in B cell lymphomas.
  • To summarize current clinical trial data for small molecule tyrosine kinase inhibitors targeting Syk, BTK, and PI3K.

Main Methods:

  • Review of preclinical rationale for targeting BCR signaling.
  • Summary of clinical trial data for tyrosine kinase inhibitors (TKIs).
  • Focus on agents targeting Spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (BTK), and phosphoinositide 3-kinase (PI3K).

Main Results:

  • Several small molecule TKIs targeting downstream BCR pathways are in clinical development.
  • Preliminary data indicate significant activity in relapsed and refractory B cell lymphomas.
  • Agents targeting Syk, BTK, and PI3K are showing promising results.

Conclusions:

  • Targeting BCR signaling pathways is a viable therapeutic strategy for B cell lymphomas.
  • TKIs targeting Syk, BTK, and PI3K represent a promising new class of agents for lymphoma treatment.
  • Further clinical development is warranted for these targeted therapies.

More Related Videos

Murine Model of CD40-activation of B cells12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...